![]() |
| May 25, 2010 |
|
During 2008, an estimated 604,808 drug-related ED visits were made by young adults aged 18 to 24, of which 6.3 percent (38,036 visits) involved a suicide attempt. Many of the ED visits for drug-related suicide attempts involved multiple drugs, with an overall average of 2.2 drugs (including alcohol) per ED visit (2.4 for males; 2.0 for females). Almost three of every five (57.6 percent) of the ED visits for drug-related suicide attempts were made by females.
Pharmaceuticals were involved in 92.8 percent of ED visits for drug-related suicide attempts among young adults (Table 1). Alcohol, sometimes combined with other drugs, was involved in 3 out of 10 (30.3 percent) visits. Illicit drugs were involved in more than one fifth of these visits (21.9 percent), with marijuana (14.7 percent) and cocaine (6.2 percent) accounting for the largest proportions of these substances.7
| Drug Category | Estimated Number of ED Visits** |
Percent of Visits** |
|---|---|---|
| Total ED Visits | 38,036 | 100.0% |
| Major Substances of Abuse | 15,605 | 41.0% |
| Alcohol*** | 11,523 | 30.3% |
| Alcohol Combined with Drugs | 11,390 | 29.9% |
| Illicit Drugs | 8,347 | 21.9% |
| Marijuana | 5,576 | 14.7% |
| Cocaine | 2,370 | 6.2% |
| Pharmaceuticals | 35,283 | 92.8% |
| Anti-anxiety Drugs (e.g., Anxiolytics, Sedatives, and Hypnotics) |
10,237 | 26.9% |
| Benzodiazepines (e.g., Alprazolam) | 6,363 | 16.7% |
| Antidepressants | 6,700 | 17.6% |
| Selective Serotonin Reuptake Inhibitors |
4,466 | 11.7% |
| Antipsychotics (e.g., Quetiapine) | 4,891 | 12.9% |
| Narcotic Painkillers (e.g., Oxycodone) | 4,324 | 11.4% |
| Acetaminophen Products | 5,761 | 15.1% |
| Ibuprofen Products | 4,314 | 11.3% |
| Anticonvulsants | 3,539 | 9.3% |
| * Other drugs involved in suicide attempts were all found at levels of less than 5 percent, and usually less than 1 percent; therefore, data are not shown. ** Because multiple drugs may be involved in each visit, estimates of visits by drug may add to more than the total, and percentages may add to more than 100 percent. *** The alcohol category includes visits involving alcohol taken in combination with other drugs for all patients and visits involving just alcohol for patients aged 18 to 20. DAWN does not track alcohol-only visits for patients aged 21 or older. Source: 2008 (08/2009 update) SAMHSA Drug Abuse Warning Network (DAWN). |
Anti-anxiety drugs were involved in 26.9 percent of the visits, the majority of which were related to use of benzodiazepines (16.7 percent). Antidepressants were involved in 17.6 percent of visits; 11.7 percent were accounted for by selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine. Antipsychotics, narcotic painkillers, and anticonvulsants each were involved in about 1 out of 10 visits (12.9, 11.4, and 9.3 percent, respectively). Pain medications containing acetaminophen or ibuprofen as their main ingredient were involved in 15.1 percent and 11.3 percent of ED visits for drug-related suicide attempts among young adults, respectively. Other prescription and over-the-counter (OTC) pharmaceuticals involved in suicide attempts among young adults typically were found at levels less than 5 percent, including respiratory agents, gastrointestinal agents (e.g., laxatives), and cardiovascular agents (data not shown).
The drugs involved in ED visits for drug-related suicide attempts varied by gender (Figure 1). For example, in comparison with females, males had significantly higher proportions of visits involving illicit drugs (29.6 vs. 14.8 percent) and antipsychotics (18.1 vs. 9.2 percent). Although not statistically significant, a higher percentage of visits made by males involved alcohol in comparison with visits made by females (38.5 vs. 23.0 percent). Antidepressants were indicated in 19.4 percent of visits by females compared with 15.6 percent of ED visits by males.
|
| Substance | Male | Female |
|---|---|---|
| Alcohol* | 38.5% | 23.0% |
| Illicit Drugs | 29.6% | 14.8% |
| Anti-anxiety Drugs | 30.7% | 22.6% |
| Antidepressants | 15.6% | 19.4% |
| Antipsychotics | 18.1% | 9.2% |
| Narcotic Painkillers | 12.0% | 11.1% |
| Acetaminophen Products | 14.0% | 16.3% |
| Ibuprofen Products | 9.5% | 12.9% |
| * The alcohol category includes visits involving alcohol taken in combination with other drugs for all patients and visits involving just alcohol for patients aged 18 to 20. DAWN does not track alcohol-only visits for patients aged 21 or older. Source: 2008 (08/2009 update) SAMHSA Drug Abuse Warning Network (DAWN). |
Follow-up care in DAWN is defined as admission to an inpatient unit in the hospital, transfer to another health care facility, or referral to detoxification. Slightly less than three fourths (72.1 percent) of the ED visits for drug-related suicide attempts among young adults ended with evidence of follow-up care. More than 75 percent of visits involving acetaminophen products, anti-anxiety drugs, ibuprofen products, and antidepressants resulted in evidence of follow-up care compared with about 65 percent of visits involving narcotic painkillers and about 60 percent of visits involving alcohol and illicit drugs (Figure 2).
![]() |
| Substance | Follow-up | No Follow-up |
|---|---|---|
| Alcohol* | 59.4% | 40.6% |
| Illicit Drugs | 60.1% | 39.9% |
| Anti-anxiety Drugs | 77.7% | 22.3% |
| Antidepressants | 80.3% | 19.7% |
| Narcotic Painkillers | 64.6% | 35.4% |
| Acetaminophen Products | 76.1% | 23.9% |
| Ibuprofen Products | 78.9% | 21.1% |
| * The alcohol category includes visits involving alcohol taken in combination with other drugs for all patients and visits involving just alcohol for patients aged 18 to 20. DAWN does not track alcohol-only visits for patients aged 21 or older. Source: 2008 (08/2009 update) SAMHSA Drug Abuse Warning Network (DAWN). |
EDs are a key access point to the health care system for people who have attempted suicide and are a strategic location for providing timely intervention.8 Although most drug-related ED visits involving suicide attempts among young adults had evidence of follow-up care, a significant minority proportion (nearly 30 percent) did not. Additionally, about 4 in 10 visits associated with alcohol and illicit drugs ended with no evidence of follow-up. These findings may point to the need for increased education and awareness among ED staff about the importance of follow-up care for involvement with these particular substances.
Among young adults, females constituted a larger proportion of ED visits for drug-related suicide attempts than males, and the drugs involved with these attempts differed by gender. Thus, it may be important for health care professionals to consider these gender differences as they triage, assess, and intervene with patients and plan for aftercare. Continuing research is needed to examine how assessments, treatment interventions, and prevention programs can be tailored to account for demographic characteristics (e.g., age, gender, race) and other critical factors (e.g., mental health problems, alcohol and drug use, employment status) associated with this population.
| The Drug Abuse Warning Network (DAWN) is a public health surveillance system that monitors drug-related morbidity and mortality. DAWN uses a probability sample of hospitals to produce estimates of drug-related emergency department (ED) visits for the United States and selected metropolitan areas annually. DAWN also produces annual profiles of drug-related deaths reviewed by medical examiners or coroners in selected metropolitan areas and States. Any ED visit related to recent drug use is included in DAWN. All types of drugs—licit and illicit—are covered. Alcohol is included for adults when it occurs with another drug. Alcohol always is reported for minors even if no other drug is present. DAWN's method of classifying drugs was derived from the Multum Lexicon, Copyright 2008, Multum Information Services, Inc. The Multum Licensing Agreement can be found in DAWN annual publications at http://www.multum.com/license.htm. DAWN is one of three major surveys conducted by the Substance Abuse and Mental Health Services Administration's Office of Applied Studies (SAMHSA/OAS). For more information on other OAS surveys, go to http://oas.samhsa.gov. SAMHSA has contracts with Westat (Rockville, MD) and RTI International (Research Triangle Park, NC) to operate the DAWN system and produce publications. For publications and additional information about DAWN, go to http://DAWNinfo.samhsa.gov/. |
| The DAWN Report is published periodically by the Office of Applied Studies, Substance Abuse and Mental Health Services Administration (SAMHSA). All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Additional copies of this report or other reports from the Office of Applied Studies are available online: http://oas.samhsa.gov/. Citation of the source is appreciated. For questions about this report, please e-mail: shortreports@samhsa.hhs.gov.
DAWN_002 |
This page was last updated on September 29, 2009. |